BridgeBio Oncology Therapeutics, Inc.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- Ticker
- BBOT
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- -
- Headquarters
- 256 East Grand Avenue, South San Francisco, CA, United States, 94080
- Employees
- 92
- Website
- https://bbotx.com
Metrics
Analyst Insights & forecasts
Based on information from 12 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$0.49 | -$526.11 | -$0.71 |
| Expected | -$0.66 | -$0.51 | -$0.55 |
| Surprise | 25.76% | -102,777.32% | -29.09% |
| Beat | Missed | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-56.5M | $-34.2M | -39.46% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a BridgeBio Oncology Therapeutics, Inc. share?
BridgeBio Oncology Therapeutics, Inc. shares are currently traded for undefined per share.
02How many shares does BridgeBio Oncology Therapeutics, Inc. have?
BridgeBio Oncology Therapeutics, Inc. currently has 80.3M shares.
03Does BridgeBio Oncology Therapeutics, Inc. pay dividends?
No, BridgeBio Oncology Therapeutics, Inc. doesn't pay dividends.
04What is BridgeBio Oncology Therapeutics, Inc. 52 week high?
BridgeBio Oncology Therapeutics, Inc. 52 week high is $14.87.
05What is BridgeBio Oncology Therapeutics, Inc. 52 week low?
BridgeBio Oncology Therapeutics, Inc. 52 week low is $1.79.
06What is the 200-day moving average of BridgeBio Oncology Therapeutics, Inc.?
BridgeBio Oncology Therapeutics, Inc. 200-day moving average is $7.49.
07Who is BridgeBio Oncology Therapeutics, Inc. CEO?
The CEO of BridgeBio Oncology Therapeutics, Inc. is -.
08How many employees BridgeBio Oncology Therapeutics, Inc. has?
BridgeBio Oncology Therapeutics, Inc. has 92 employees.
09What is the market cap of BridgeBio Oncology Therapeutics, Inc.?
The market cap of BridgeBio Oncology Therapeutics, Inc. is $149M.
10What is the P/E of BridgeBio Oncology Therapeutics, Inc.?
The current P/E of BridgeBio Oncology Therapeutics, Inc. is 3.51.
11What is the EPS of BridgeBio Oncology Therapeutics, Inc.?
The EPS of BridgeBio Oncology Therapeutics, Inc. is $0.53.
12What is the PEG Ratio of BridgeBio Oncology Therapeutics, Inc.?
The PEG Ratio of BridgeBio Oncology Therapeutics, Inc. is null.
13What do analysts say about BridgeBio Oncology Therapeutics, Inc.?
According to the analysts BridgeBio Oncology Therapeutics, Inc. is considered a buy.


